Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review
Standard
Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review. / Fischer, Benedikt; Hall, Wayne; Fidalgo, Thiago M; Hoch, Eva; Foll, Bernard Le; Medina-Mora, Maria-Elena; Reimer, Jens; Tibbo, Philip G; Jutras-Aswad, Didier.
In: J DUAL DIAGN, Vol. 19, No. 2-3, 2023, p. 71-96.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Recommendations for Reducing the Risk of Cannabis Use-Related Adverse Psychosis Outcomes: A Public Mental Health-Oriented Evidence Review
AU - Fischer, Benedikt
AU - Hall, Wayne
AU - Fidalgo, Thiago M
AU - Hoch, Eva
AU - Foll, Bernard Le
AU - Medina-Mora, Maria-Elena
AU - Reimer, Jens
AU - Tibbo, Philip G
AU - Jutras-Aswad, Didier
PY - 2023
Y1 - 2023
N2 - Objective: Cannabis use is increasingly normalized; psychosis is a major adverse health outcome. We reviewed evidence on cannabis use-related risk factors for psychosis outcomes at different stages toward recommendations for risk reduction by individuals involved in cannabis use. Methods: We searched primary databases for pertinent literature/data 2016 onward, principally relying on reviews and high-quality studies which were narratively summarized and quality-graded; recommendations were developed by international expert consensus. Results: Genetic risks, and mental health/substance use problem histories elevate the risks for cannabis-related psychosis. Early age-of-use-onset, frequency-of-use, product composition (i.e., THC potency), use mode and other substance co-use all influence psychosis risks; the protective effects of CBD are uncertain. Continuous cannabis use may adversely affect psychosis-related treatment and medication effects. Risk factor combinations further amplify the odds of adverse psychosis outcomes. Conclusions: Reductions in the identified cannabis-related risks factors-short of abstinence-may decrease risks of related adverse psychosis outcomes, and thereby protect cannabis users' health.
AB - Objective: Cannabis use is increasingly normalized; psychosis is a major adverse health outcome. We reviewed evidence on cannabis use-related risk factors for psychosis outcomes at different stages toward recommendations for risk reduction by individuals involved in cannabis use. Methods: We searched primary databases for pertinent literature/data 2016 onward, principally relying on reviews and high-quality studies which were narratively summarized and quality-graded; recommendations were developed by international expert consensus. Results: Genetic risks, and mental health/substance use problem histories elevate the risks for cannabis-related psychosis. Early age-of-use-onset, frequency-of-use, product composition (i.e., THC potency), use mode and other substance co-use all influence psychosis risks; the protective effects of CBD are uncertain. Continuous cannabis use may adversely affect psychosis-related treatment and medication effects. Risk factor combinations further amplify the odds of adverse psychosis outcomes. Conclusions: Reductions in the identified cannabis-related risks factors-short of abstinence-may decrease risks of related adverse psychosis outcomes, and thereby protect cannabis users' health.
KW - Humans
KW - Cannabis/adverse effects
KW - Mental Health
KW - Psychotic Disorders/therapy
KW - Substance-Related Disorders
KW - Risk Factors
U2 - 10.1080/15504263.2023.2226588
DO - 10.1080/15504263.2023.2226588
M3 - SCORING: Review article
C2 - 37450645
VL - 19
SP - 71
EP - 96
JO - J DUAL DIAGN
JF - J DUAL DIAGN
SN - 1550-4263
IS - 2-3
ER -
